Enanta Pharmaceuticals to Present Phase 2 Zelicapavir RSV Data at IDWeek 2026
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will present clinical trial results for zelicapavir, its oral, once-daily treatment candidate for respiratory syncytial virus (RSV), at the IDWeek 2026 conference in October.
The poster presentation will share Phase 2 trial data from a global study involving high-risk adults. The study examined how zelicapavir affected the time to complete RSV symptom resolution, hospitalization rates, and viral load compared with a placebo.
The presentation by Dr. Christopher E. Harris is scheduled for October 22, 2026, in Washington, D.C. Shares of Enanta Pharmaceuticals were trading at $12.30, down 1.60% today.
Key points
- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will present Phase 2 clinical trial data for zelicapavir at IDWeek 2026 on October 22, 2026.
- Zelicapavir is an experimental oral, once-daily N-protein inhibitor under development to treat respiratory syncytial virus (RSV).
- The Phase 2 trial evaluated zelicapavir's effects on RSV symptom resolution, hospitalization, and viral load in high-risk adults versus placebo.
- Dr. Christopher E. Harris will present the findings during the Novel Agents poster session at the conference in Washington, D.C.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
When is Enanta Pharmaceuticals presenting its RSV drug data?
Enanta Pharmaceuticals will present Phase 2 data for zelicapavir on October 22, 2026, between 12:15 PM and 1:30 PM ET at IDWeek 2026 in Washington, D.C.
What is zelicapavir?
Zelicapavir is an investigational oral, once-daily N-protein inhibitor being developed by Enanta Pharmaceuticals to treat respiratory syncytial virus (RSV).
What did the Phase 2 trial of zelicapavir measure?
The Phase 2 trial evaluated zelicapavir in high-risk adults with RSV, measuring its effect on symptom resolution, hospitalization, and viral load compared to a placebo.